Anthony Tolcher

Dr. Tolcher is a medical oncologist who has more than 25 years of early drug development and clinical trial experience and is currently a principal investigator for 20 Phase 1 clinical studies. He is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology; and has chaired the Developmental Therapeutics Review Committee for the American Society for Clinical Oncology Annual Scientific Program. In addition, he is a member of more than 20 scientific advisory boards for both large and small pharmaceutical companies and serves as a board member for two biotechnology companies. Dr. Tolcher has been involved in many of the initial Phase 1 studies of new agents that subsequently were FDA approved for the treatment of cancer. Some of these include pembrolizumab (Keytruda®), copanlisib (Aliqopa®), trastuzumab emtansine (Kadcyla®), regorafenib (Stivarga®), liposomal vincristine (Marqibo®), cabazitaxel (Jevtana®), carfilzomib (Kyprolis®), gefitinib (Iressa®), erlotinib (Tarceva®) and eribulin (Halaven®). Dr. Tolcher is CEO and founder of NEXT Oncology, a San Antonio-based company focused on accelerating breakthrough medicines for cancer by developing and supporting Phase 1 clinical trial programs in oncology research. In 2007, Dr. Tolcher co-founded South Texas Accelerated Research Therapeutics (START), which operates one of the world's largest Phase 1 and early drug development oncology programs. He served as president of the company until 2018.

Dr. Tolcher has over 100 peer-reviewed publications in scientific journals, such as Nature, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Oncology and Clinical Cancer Research, and he is an author of nine book chapters.